- Diagnostic Différentiel
Drug Information for DICLOFENAC POTASSIUM TABLETS50 mg (Mylan Pharmaceuticals Inc.): DOSAGE AND ADMINISTRATION
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Liens externes liés à DICLOFENAC POTASSIUM TABLETS50 mg (Mylan Pharmaceuticals Inc.)
Carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
After observing the response to initial therapy with diclofenac potassium tablets the dose and frequency should be adjusted to suit an individual patient's needs.
For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg t.i.d. With experience, physicians may find that in some patients an initial dose of 100 mg of diclofenac potassium tablets, followed by 50 mg doses, will provide better relief.
For the relief of osteoarthritis the recommended dosage is 100 to 150 mg/day in divided doses, 50 mg b.i.d. or t.i.d.
For the relief of rheumatoid arthritis the recommended dosage is 150 to 200 mg/day in divided doses, 50 mg t.i.d. or q.i.d.
Different formulations of diclofenac [Voltaren®Voltaren® is a registered trademark of Novartis (diclofenac sodium enteric-coated tablets); Voltaren®-XRVoltaren®-XR is a registered trademark of Novartis (diclofenac sodium extended-release tablets); Cataflam®Cataflam® is a registered trademark of Novartis (diclofenac potassium immediate-release tablets)] are not necessarily bioequivalent even if the milligram strength is the same.
- Drug Information Provided by National Library of Medicine (NLM).